Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Physical inactivity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Physical inactivity. Displaying page 1 of 1.
    EudraCT Number: 2016-003501-33 Sponsor Protocol Number: DECOLAD Start Date*: 2016-12-01
    Sponsor Name:AntibioTx ApS
    Full Title: A prospective, single center, randomized, double-blind, placebo controlled study in two phases to evaluate the safety and efficacy of ATx201 as a topical antibiotic agent
    Medical condition: AntibioTx has developed a topical product (ATx201) for treatment of infected eczema and infected atopic dermatitis. These infections are predominantly caused by Staphyllococcus aureus and various s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10040788 Skin and subcutaneous tissue bacterial infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004884-30 Sponsor Protocol Number: P13-04/BP1.4979 Start Date*: 2017-12-07
    Sponsor Name:BIOPROJET PHARMA
    Full Title: Randomized double blind parallel groups sequential, placebo controlled, trial assessing the efficacy and safety of BP1.4979 in Resteless Legs Syndrome (RLS).
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10058920 Restless legs syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002140-10 Sponsor Protocol Number: N01125 Start Date*: 2005-08-24
    Sponsor Name:UCB Pharma S.A.
    Full Title: An open-label, multi-center, follow-up trial to evaluate long-term safety and efficacy of brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in s...
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) DE (Completed) GB (Completed) FI (Completed) ES (Completed) IT (Completed) SE (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015602-18 Sponsor Protocol Number: DM-ET-DT Start Date*: 2010-09-21
    Sponsor Name:Actelion Pharmaceuticals
    Full Title: Diabetes and vascular complications: the role of endothelin and physical inactivity’
    Medical condition: type 2 diabetes mellius
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001433-98 Sponsor Protocol Number: N01315 Start Date*: 2008-08-11
    Sponsor Name:UCB BioSciences, Inc
    Full Title: An open-label, multinational, multicenter, follow-up study to evaluate the long-term safety and efficacy of brivaracetam, used at a flexible dose up to a maximum of 200 mg/day, in subjects aged 16 ...
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SE (Completed) ES (Completed) FR (Completed) HU (Completed) FI (Prematurely Ended) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004714-27 Sponsor Protocol Number: N01258 Start Date*: 2011-10-05
    Sponsor Name:UCB Biosciences, Inc.
    Full Title: A Multicenter, Open-label, Four-arm, Randomized trial, Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepilep...
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006558-24 Sponsor Protocol Number: SP935 Start Date*: 2008-04-14
    Sponsor Name:Schwarz Biosciences GmbH
    Full Title: PHASE 3B, OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE PRACTICABILITY AND TOLERABILITY OF SWITCHING SUBJECTS OVERNIGHT FROM PRAMIPEXOLE OR ROPINIROLE TO ROTIGOTINE TRANSDERMAL PATCH AND ITS EFFECT O...
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058920 Restless legs syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000144-14 Sponsor Protocol Number: N01276 Start Date*: 2008-07-14
    Sponsor Name:UCB Inc
    Full Title: An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to...
    Medical condition: Partial onset seizures with or without secondary generalization.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004702-42 Sponsor Protocol Number: RG101-04 Start Date*: 2016-01-15
    Sponsor Name:Regulus Therapeutics Inc.
    Full Title: A Multi-Center, Parallel Group, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of a Single Subcutaneous Injection of RG-101 Combined with Oral GSK2878175 Taken Once Daily for 6, 9, o...
    Medical condition: Treatment Naïve, Genotype 1 and 3, Chronic Hepatitis C Patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10076831 Chronic hepatitis C genotype 3 LLT
    19.0 100000004862 10074391 Chronic hepatitis C virus genotype 1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GR (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004475-31 Sponsor Protocol Number: THN102-202 Start Date*: 2018-04-17
    Sponsor Name:Theranexus S.A.
    Full Title: Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associa...
    Medical condition: Excessive daytime sleepiness associated with Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10041349 Somnolence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-004239-21 Sponsor Protocol Number: PAC325 Start Date*: 2012-12-03
    Sponsor Name:CTI BioPharma Corp.
    Full Title: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemi...
    Medical condition: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004000-19 Sponsor Protocol Number: PAC326 Start Date*: 2014-05-12
    Sponsor Name:CTI BioPharma Corp.
    Full Title: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Ess...
    Medical condition: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Completed) DE (Temporarily Halted) HU (Prematurely Ended) CZ (Prematurely Ended) NL (Temporarily Halted) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000145-58 Sponsor Protocol Number: N01306 Start Date*: 2008-07-11
    Sponsor Name:UCB Pharma S.A.
    Full Title: An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to...
    Medical condition: Partial onset seizures with or without secondary generalization.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) HU (Prematurely Ended) FI (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002616-96 Sponsor Protocol Number: D3561C00087 Start Date*: 2006-08-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIb, efficacy, and safety study of rosuvastatin in children and adolescents 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH): a 12-week, double-blind, randomiz...
    Medical condition: Heterozygous familial hypercholesterolemia (HeFH) is a frequent, inherited disorder of lipoprotein metabolism caused by mutations in the LDL receptor gene. The risk of CHD is approximately 50% by 5...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 09:44:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA